Barclays keeps Overweight rating and $9 price target on Sangamo (SGMO), noting that while Pfizer’s (PFE) decision to discontinue HemoA gene therapy came as a big surprise given the prior comments of BLA filing in early FY25, the stock move is “overdone”. The firm notes that “limited valuation” was assigned to the HemoA program and that it sees upside from the near-term Fabry deal announcement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMO:
- Closing Bell Movers: CompoSecure gains 5% on Resolute Holdings spinoff
- Sangamo Biosciences Faces Pfizer Collaboration Termination
- Sangamo down 31% at $1.61 after Pfizer decision to terminate collaboration
- Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer
- Sangamo to receive $20M from Astellas Pharma in capsid license agreement